40
Participants
Start Date
October 29, 2019
Primary Completion Date
March 31, 2021
Study Completion Date
March 31, 2021
Metformin
Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994. It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with other drugs under the names Actoplus Met, Metaglip, Glucovance, Janumet, Kombiglyze XR, and PrandiMet
Placebo oral tablet
No therapeutic effect
RECRUITING
Rowan University School of Osteopathic Medicine, Stratford
Collaborators (1)
FRAXA Research Foundation
OTHER
University of Pennsylvania
OTHER
Rowan University
OTHER